Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/JARID2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/JARID2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/JARID2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/JARID2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/JARID2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/JARID2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/JARID2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/JARID2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/JARID2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/JARID2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000188916 | Prostate | BPH | liver development | 45/3107 | 147/18723 | 1.76e-05 | 2.18e-04 | 45 |
GO:00106112 | Prostate | BPH | regulation of cardiac muscle hypertrophy | 26/3107 | 69/18723 | 2.09e-05 | 2.55e-04 | 26 |
GO:00148973 | Prostate | BPH | striated muscle hypertrophy | 34/3107 | 102/18723 | 2.63e-05 | 3.10e-04 | 34 |
GO:00033004 | Prostate | BPH | cardiac muscle hypertrophy | 33/3107 | 99/18723 | 3.43e-05 | 3.82e-04 | 33 |
GO:00488636 | Prostate | BPH | stem cell differentiation | 55/3107 | 206/18723 | 1.56e-04 | 1.36e-03 | 55 |
GO:00349686 | Prostate | BPH | histone lysine methylation | 35/3107 | 115/18723 | 1.64e-04 | 1.42e-03 | 35 |
GO:00435025 | Prostate | BPH | regulation of muscle adaptation | 31/3107 | 98/18723 | 1.75e-04 | 1.50e-03 | 31 |
GO:00147066 | Prostate | BPH | striated muscle tissue development | 91/3107 | 384/18723 | 1.90e-04 | 1.57e-03 | 91 |
GO:009025710 | Prostate | BPH | regulation of muscle system process | 64/3107 | 252/18723 | 2.26e-04 | 1.81e-03 | 64 |
GO:00064796 | Prostate | BPH | protein methylation | 49/3107 | 181/18723 | 2.42e-04 | 1.93e-03 | 49 |
GO:00082136 | Prostate | BPH | protein alkylation | 49/3107 | 181/18723 | 2.42e-04 | 1.93e-03 | 49 |
GO:00165716 | Prostate | BPH | histone methylation | 40/3107 | 141/18723 | 3.09e-04 | 2.37e-03 | 40 |
GO:00030127 | Prostate | BPH | muscle system process | 103/3107 | 452/18723 | 3.54e-04 | 2.62e-03 | 103 |
GO:00310566 | Prostate | BPH | regulation of histone modification | 42/3107 | 152/18723 | 4.09e-04 | 2.97e-03 | 42 |
GO:00165772 | Prostate | BPH | histone demethylation | 13/3107 | 31/18723 | 7.48e-04 | 4.95e-03 | 13 |
GO:00330023 | Prostate | BPH | muscle cell proliferation | 61/3107 | 248/18723 | 7.61e-04 | 5.02e-03 | 61 |
GO:00063382 | Prostate | BPH | chromatin remodeling | 62/3107 | 255/18723 | 9.47e-04 | 5.97e-03 | 62 |
GO:00064822 | Prostate | BPH | protein demethylation | 13/3107 | 33/18723 | 1.50e-03 | 8.85e-03 | 13 |
GO:00082142 | Prostate | BPH | protein dealkylation | 13/3107 | 33/18723 | 1.50e-03 | 8.85e-03 | 13 |
GO:00485384 | Prostate | BPH | thymus development | 16/3107 | 45/18723 | 1.62e-03 | 9.39e-03 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
JARID2 | SNV | Missense_Mutation | | c.1100N>G | p.Pro367Arg | p.P367R | Q92833 | protein_coding | deleterious_low_confidence(0.02) | benign(0.168) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
JARID2 | SNV | Missense_Mutation | | c.71C>T | p.Ser24Leu | p.S24L | Q92833 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
JARID2 | SNV | Missense_Mutation | | c.550N>A | p.Glu184Lys | p.E184K | Q92833 | protein_coding | tolerated(0.06) | benign(0.022) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
JARID2 | insertion | Nonsense_Mutation | novel | c.1023_1024insTTTGGTTTTAGTGGAAGCATTTGAAA | p.Val342PhefsTer8 | p.V342Ffs*8 | Q92833 | protein_coding | | | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
JARID2 | insertion | Frame_Shift_Ins | novel | c.961_962insAGGAGCACACGCTGCAGACACCTCACTTTCTGCAGAGCTGG | p.Ser321LysfsTer30 | p.S321Kfs*30 | Q92833 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
JARID2 | insertion | Frame_Shift_Ins | novel | c.2634_2635insCAAA | p.Val879GlnfsTer21 | p.V879Qfs*21 | Q92833 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
JARID2 | insertion | In_Frame_Ins | novel | c.2635_2636insCATGTTCTGACCCATTCTTTGCCCCCA | p.Val879delinsAlaCysSerAspProPhePheAlaProIle | p.V879delinsACSDPFFAPI | Q92833 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
JARID2 | deletion | Frame_Shift_Del | novel | c.2472delN | p.Tyr826IlefsTer8 | p.Y826Ifs*8 | Q92833 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
JARID2 | insertion | Frame_Shift_Ins | novel | c.2810_2811insCC | p.Ile938ProfsTer48 | p.I938Pfs*48 | Q92833 | protein_coding | | | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
JARID2 | insertion | Nonsense_Mutation | novel | c.2812_2813insCCGTAGAAGGATGGTTCTGAGAATGAATTTCTGTGGC | p.Ile938ThrfsTer7 | p.I938Tfs*7 | Q92833 | protein_coding | | | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |